Breast cancer is pathologically demarcated by a plethora of abnormal gene profiles and transcripts that drive tumor initiation (MYC, Erb-B2 Receptor tyrosine kinase 2 (ERBB2) [6,7], tumor progression (FOS, JUNB) [8], proliferation and metastasis (epidermal growth factor receptor (EGRF)) [9,10]. The gene discussed is MYC; the disease is neoplasm.